



Personalized Medicine for Schizophrenia Spectrum Disorders

Guest Editor:

Dr. Nerisa Banaj

Laboratory of Neuropsychiatry,
Department of Clinical and
Behavioral Neurology, IRCCS
Santa Lucia Foundation, 00179
Rome, Italy

Deadline for manuscript
submissions:

15 February 2024

Message from the Guest Editor

Dear colleagues,


Schizophrenia remains one of the most debilitating diseases, affecting 20 million people worldwide.

It is well known that the chronicity of the disease has a great impact on the functional outcome and that a frank psychotic episode is usually preceded by a prodromal phase of attenuated psychotic symptoms and decline in functioning. In the prodromal phase, patients experience changes in feelings, thoughts, perceptions, and behavior. Intervention during this phase could prevent the transition to psychosis and is therefore of high relevance.

In a joint effort, the Special Issue of the *Journal of Personalized Medicine* aims to provide insights into reliable biomarkers that can be used as diagnostics or predictors of treatment outcomes and to promote tailored therapeutic interventions. Contributions will include, but are not limited to, original research articles and literature reviews dealing with biomarker identification through clinical, neuroimaging, and genetic approaches, targeted assessment tools, and pharmacotherapy, along with non-pharmacological interventions.

Nerisa Banaj
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[@JPM_MDPI](https://twitter.com/JPM_MDPI)